• Publications
  • Influence
Pharmacokinetics of oral and intravenous rifampicin during chronic administration
It was found that, due to autoinduction of its metabolizing hepatic enzymes, the systemic clearance of rifampicin increased from 5.69 to 9.03 l/h after 3 weeks of multiple dosing, and a preabsorptive process can be excluded as a cause of reduced bioavailability. Expand
The influence of CYP2D6 polymorphism and quinidine on the disposition and antitussive effect of dextromethorphan in humans
We studied the disposition of dextromethorphan in extensive and poor metabolizer subjects, as well as the effect of this polymorphism on the antitussive action of dextromethorphan.
CYP2C19 Genotype Is a Major Factor Contributing to the Highly Variable Pharmacokinetics of Voriconazole
Multiple regression analysis of voriconazole apparent oral clearance revealed that 49% of its variance can be explained solely by the CYP2C19 polymorphism (P < .0001). Expand
Pharmacokinetics, metabolism and bioavailability of the triazole antifungal agent voriconazole in relation to CYP2C19 genotype.
The pharmacokinetics of voriconazole after a single oral dose in comparison with intravenous and oral administration in healthy individuals stratified according to the cytochrome P450 (CYP) 2C19 genotype were determined and the predominant metabolic pathway is the hydroxylation that seems to be influenced by the CYP2C 19 genotype. Expand
European Pain Federation position paper on appropriate opioid use in chronic pain management
A considered attempt to empower and inform non‐specialist opioid prescribers, EFIC convened a European group of experts, drawn from a diverse range of basic science and relevant clinical disciplines, to prepare a position paper on appropriate opioid use in chronic pain. Expand
Understanding variability with voriconazole using a population pharmacokinetic approach: implications for optimal dosing.
Current dosing regimens for voriconazole result in subtherapeutic exposure in many patients without CYP2C19 LoF alleles, suggesting the need for higher doses, whereas these regimens result in supratherapeutic Exposure in a high proportion of patients with reduced CYP1C19 activity. Expand
Ritonavir increases loperamide plasma concentrations without evidence for P‐glycoprotein involvement
The antidiarrheal drug loperamide is frequently used to treat ritonavir‐associated diarrhea in patients with human immunodeficiency virus. The absence of marked central opioid effects has beenExpand
Assessment of the predictive power of genotypes for the in-vivo catalytic function of CYP2D6 in a German population.
Genotyping correctly identifies poor metabolizers, but quantitative prediction of drug metabolism capacity among extensive metabolizers is not possible and genotype was not a useful predictor of function. Expand
Opposite effects of short‐term and long‐term St John's wort intake on voriconazole pharmacokinetics
Constituents of St John's wort (SJW) in vivo induce the cytochrome P450 (CYP) isozymes 3A4, 2C9, and 2C19 but in vitro were shown to inhibit them. This study investigates both short‐ and long‐termExpand
Potent cytochrome P450 2C19 genotype–related interaction between voriconazole and the cytochrome P450 3A4 inhibitor ritonavir
The effect of the potent CYP3A4 inhibitor ritonavir after short‐term administration on voriconazole pharmacokinetics in extensive metabolizer (EMs) and poor metabolizers (PMs) of CYP2C19 is assessed. Expand